AbbVie’s 2024 results and guidance point to modest growth in early‐2025.  Q1 2024 net revenues were $12.310B ([news.abbvie.com](https://news.abbvie.com/2024-04-26-AbbVie-Reports-First-Quarter-2024-Financial-Results#:~:text=Net%20revenues%20%20,164)) and key immunology drugs (Skyrizi, Rinvoq) grew ~50% YoY ([news.abbvie.com](https://news.abbvie.com/2024-04-26-AbbVie-Reports-First-Quarter-2024-Financial-Results#:~:text=basis%2C%20or%2011,percent%20on%20an%20operational%20basis)), offsetting Humira declines.  Management notes “significant momentum” entering 2025 and expects revenues to exceed prior peaks ([news.abbvie.com](https://news.abbvie.com/2025-01-31-AbbVie-Reports-Full-Year-and-Fourth-Quarter-2024-Financial-Results#:~:text=,Humira%20loss%20of%20exclusivity)).  Based on that, we assume Q1 2025 revenue ~6% above Q1 2024, or about $13.05B.  Assuming an ~25% operating margin (vs 22.7% in Q1 2024 ([news.abbvie.com](https://news.abbvie.com/2024-04-26-AbbVie-Reports-First-Quarter-2024-Financial-Results#:~:text=Operating%20earnings%20%20,1%2C755))) yields ~$3.13B operating income.  Adding back ~$1.80B of D&A gives EBITDA ~$4.90B.  After interest/taxes, net income is forecast ~ $1.56B (GAAP) (Q1 2024 GAAP net was $1.369B ([news.abbvie.com](https://news.abbvie.com/2024-04-26-AbbVie-Reports-First-Quarter-2024-Financial-Results#:~:text=,77))), or ~$0.88 EPS (1.78B shares).  We estimate free cash flow around $3.95B (Q1 2024 FCF was ~$3.85B).  Our projections are summarized below:

| Company | Year | Quarter | Revenue         | EBITDA         | Operating Income | Net Income     | Free Cash Flow | EPS   |
|---------|------|---------|-----------------|----------------|------------------|----------------|----------------|-------|
| AbbVie  | 2025 | 1       | 13,050,000,000  | 4,900,000,000  | 3,130,000,000    | 1,560,000,000  | 3,950,000,000  | 0.88  |

**Sources:** AbbVie 10-Q and earnings releases (Q1–Q4 2024) ([news.abbvie.com](https://news.abbvie.com/2024-04-26-AbbVie-Reports-First-Quarter-2024-Financial-Results#:~:text=Net%20revenues%20%20,164)) ([news.abbvie.com](https://news.abbvie.com/2025-01-31-AbbVie-Reports-Full-Year-and-Fourth-Quarter-2024-Financial-Results#:~:text=,Humira%20loss%20of%20exclusivity)); industry news ([news.abbvie.com](https://news.abbvie.com/2024-04-26-AbbVie-Reports-First-Quarter-2024-Financial-Results#:~:text=basis%2C%20or%2011,percent%20on%20an%20operational%20basis)).